Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer
Carlos Quezada-Ruiz, M.D., F.A.S.R.S., an internationally recognized retina specialist and experienced drug development leader, has been appointed Chief Medical Officer at Alkeus Pharmaceuticals.
He succeeds Seemi Khan, M.D., M.P.H., M.B.A., who moved to the newly created role of Chief Development and Strategy Officer.
Alkeus is preparing for a global Phase 3 registrational study of gildeuretinol, an investigational oral therapy targeting Stargardt disease, which has breakthrough designation.
Dr. Quezada-Ruiz has significant experience from prior leadership roles at 4D Molecular Therapeutics and Genentech/Roche, contributing to major advances in ophthalmology treatments.
His appointment underscores Alkeus' commitment to developing innovative therapies for inherited retinal diseases and preserving vision in people with Stargardt disease.
The company emphasizes the urgent unmet need for safe and effective treatment options for Stargardt disease, a genetic condition causing severe vision loss with no current approved treatment.
Dr. Quezada-Ruiz will lead clinical research and development efforts, aiming to advance gildeuretinol as a potential standard-of-care oral therapy to help preserve retinal structure and visual function.
The announcement was made on December 2, 2025, and highlights Alkeus' strategic expansion of its leadership to accelerate therapy development.